Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
Company to Webcast Fireside Chat on Wednesday, December 12 at 3:40 p.m. ET
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference in New York, NY on Wednesday, December 12.
Presentation Details
Date: Wednesday, December 12, 2018
Time: 3:40 p.m. ET
Location: Mandarin Oriental New York Hotel, New York City
Room: North Salon II
Webcast:
To access the live and archived audio webcast of the fireside chat, visit the section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit .
Investor Contact:
Joey Perrone
Director, Finance & Investor Relations
Aeglea BioTherapeutics
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
